- Home
- ACLS vs IBRX Comparison
ACLS vs IBRX Comparison
Compare ACLS & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLS
- IBRX
- Stock Information
- Founded
- ACLS 1995
- IBRX 2014
- Country
- ACLS United States
- IBRX United States
- Employees
- ACLS N/A
- IBRX N/A
- Industry
- ACLS Industrial Machinery/Components
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACLS Technology
- IBRX Health Care
- Exchange
- ACLS Nasdaq
- IBRX Nasdaq
- Market Cap
- ACLS 2.2B
- IBRX 2.3B
- IPO Year
- ACLS 2000
- IBRX N/A
- Fundamental
- Price
- ACLS $78.32
- IBRX $2.51
- Analyst Decision
- ACLS Buy
- IBRX Strong Buy
- Analyst Count
- ACLS 5
- IBRX 5
- Target Price
- ACLS $90.00
- IBRX $11.40
- AVG Volume (30 Days)
- ACLS 564.8K
- IBRX 7.6M
- Earning Date
- ACLS 08-05-2025
- IBRX 08-05-2025
- Dividend Yield
- ACLS N/A
- IBRX N/A
- EPS Growth
- ACLS N/A
- IBRX N/A
- EPS
- ACLS 4.91
- IBRX N/A
- Revenue
- ACLS $896,089,000.00
- IBRX $56,600,000.00
- Revenue This Year
- ACLS N/A
- IBRX $567.98
- Revenue Next Year
- ACLS $7.41
- IBRX $160.56
- P/E Ratio
- ACLS $16.18
- IBRX N/A
- Revenue Growth
- ACLS N/A
- IBRX 4227.22
- 52 Week Low
- ACLS $40.40
- IBRX $1.83
- 52 Week High
- ACLS $117.57
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- ACLS 62.21
- IBRX 44.54
- Support Level
- ACLS $74.88
- IBRX $2.33
- Resistance Level
- ACLS $80.48
- IBRX $2.46
- Average True Range (ATR)
- ACLS 3.22
- IBRX 0.15
- MACD
- ACLS 0.53
- IBRX -0.02
- Stochastic Oscillator
- ACLS 73.06
- IBRX 23.12
About ACLS Axcelis Technologies Inc.
Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.